♑️ Kurios Kat (@KathrenGPearce) header
♑️ Kurios Kat (@KathrenGPearce) profile picture

a kurios kat ... appreciate our watch dogs

Indepent Mind
Joined May 2010
Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)Photo by ♑️ Kurios Kat (@KathrenGPearce)
Let’s make this available in the US! #rightotryus #gbm #freezeyourtumor #dcvaxforbraelyn #NWBO #DCVax #cancersurvivors Thank you @HollensbeAmanda 💖
Replying to @JR31415926535
I started finding more long-term survivors. This was probably the biggest change in my thinking.@ThomasOwenMcCa1 wasn’t alone. Brad Silver received DCVax-L in one of the earliest trials after being diagnosed with GBM in his early 30s. He’s now a 23-year survivor. Jamil Newirth was diagnosed at 32 and given approximately 17 months to live. He received UCLA’s personalized dendritic-cell vaccine and was profiled by UCLA more than a decade later, alive and thriving. Sarah Rigby was diagnosed with GBM in 2011 and has been documented more than 15 years later as a long-term DCVax patient. Nigel French was diagnosed with GBM in 2015, entered the DCVax-L trial at King’s College Hospital and was subsequently documented in long-term remission. Kat Charles was diagnosed with grade 4 GBM in 2013 and at one point was told she had only three months to live. She later obtained a personalized dendritic-cell vaccine and continued receiving maintenance booster injections. More than a decade later, hers remains an extraordinary long-term-survivor story. And I found other early UCLA dendritic-cell-vaccine survivors, including Jennifer Sugioka, Elijah Luyten and Gallia Kistler. Suddenly Thomas didn’t look like one isolated anomaly anymore. I was finding a group of people who had received this type of dendritic-cell vaccine and experienced extraordinary survival — 10 years, 12 years, 20-plus years — including patients with many years without recurrence. And there is something especially important about these early survivors: Many of them didn’t receive Hiltonol. Some were treated years before the later UCLA study combining dendritic-cell vaccination with poly-ICLC. In other words, the extraordinary long-term survivors already existed before these newer combinations were being used. And that made the newer research even more exciting to me. If some patients became 10-, 15- and even 20-plus-year survivors with the earlier vaccine approaches, what might be possible if researchers can now strengthen that immune response even further? That’s the question that gives me hope. Then came Marnix Bosch’s July 3, 2026 presentation. At the British Neuro-Oncology Society meeting, Bosch presented new analyses using individual-patient data that hadn’t been available for the original Phase III analysis. Researchers were now able to match DCVax patients much more precisely with patients from three randomized GBM trials based on important prognostic characteristics. Across several propensity-score-matching approaches, the estimated survival advantage associated with DCVax-L was 3.4 to 6.3 months, rather than the original 2.8 months. Other statistical approaches produced similar results. Their overall conclusion was that the original analysis had likely underestimated the survival benefit associated with DCVax-L. Was that encouraging to me? Absolutely. But I want to be honest: an extra handful of months still isn’t what gives me hope. Whether the median advantage is three months or six months, I don’t want six extra months for my daughter. I want her to live a long, full life. What the newer analysis did was strengthen my confidence that DCVax has a real treatment effect and that its original benefit may have been underestimated. But my hope comes from the long tail. At five years, 13% of newly diagnosed GBM patients receiving DCVax were alive compared with 5.7% of the external controls — more than double. And now I know of some of the people represented by that tail. Brad. Thomas. Jamil. Sarah. Nigel. Kat. Jennifer. Elijah. Gallia. Those are the people I think about.
1
1
5
173
🎄🎁 LET’S MAKE THIS THE BIGGEST YEAR YET! Today, Braelyn and I are delivering neighborhood flyers for her 4TH ANNUAL CHRISTMAS TOY DRIVE benefiting Prisma Health Children’s Hospital! ❤️ Inspired by her own hospitalization at age 16, Braelyn started this tradition in 2023 to bring Christmas joy to other hospitalized children. Since then, she’s collected and delivered THOUSANDS of toys and gifts! Donations have already started arriving, and we’re incredibly grateful! ❤️ Now it’s time to kick things into HIGH GEAR! 🎁 Toys, games, books, personal items, PJ’s, & gifts for babies through teens! 📅 Deadline: DECEMBER 11 📬 Wish list and mailing details in the flyer! Please donate if you can, SHARE, and help us make Braelyn’s 4th annual toy drive her BIGGEST YET! Every child deserves a little Christmas magic. 🎄❤️ Mail to: Braelyn Hollensbe PO Box 7 Clemson, SC 29631
11
37
4
189
3,672
Like driving FSD Supervised … occasionally it makes a hair brained decision like it didn’t even read the sign that says “No U-Turn” 👀
微软这次 M365 宕机超过 12 个小时,外网都在吃瓜,但真正让人后背发凉的,是 Blind 上一位微软内部员工爆出来的细节。 据说故障最严重的时候,连微软内部用来抢修事故的 IcM 工具自己都挂了,根本加载不出来。外面的人还在猜到底是哪次发版翻车,还是哪个 AI 脚本失控,但干活的人心里都清楚,这坑早就埋下了。 过去整整两年,管理层眼里几乎只剩下一件事:快点把 AI 功能端上来。至于维护 M365 核心底座的稳定性?在现在的考评体系里就是纯纯的死胡同,干得再好也拿不到晋升,每年涨薪连 5% 都不到。 几轮裁员加上主动离职,那些真正知道底层老系统是怎么一根线一根线接起来的资深工程师,基本走光了。 结果就是,以前 45 分钟就能搞定的版本回滚,现在硬生生拖了 5 个小时。一群已经快熬干的工程师凌晨 3 点挂在语音会议里,对着两年前离职的人留下的“黑盒服务”干瞪眼,根本不知道从哪下手。 最讽刺的是,这种操作现在在硅谷大厂里几乎成了通病。一边把懂底层架构的老兵当成高成本包袱清出去,一边把所有资源砸向最能拉高股价的 AI 叙事。 上面只顾着往顶层狂加新功能,底下的承重墙被拆得七零八落也没人管。平时风平浪静看不出来,真到了半夜出事的那一刻,连修的人都找不到了。😂
25
People, technology, processes … some things don’t change over time. Critical thinking remains the value proposition.
So let me get this straight. 2021: Biden's infrastructure law puts $5B into FAA air traffic control facilities. That means towers and buildings. It doesn't replace the decades-old copper-and-switches network that connects them. 2023: The FAA hires Verizon for $2.4B to build that replacement network. Two years later it still isn't running. Project 2025 calls for spinning air traffic control out of the FAA and privatizing it if possible. 2025: DOGE fires about 400 FAA staff, including maintenance mechanics at 18 air traffic control facilities that were already short on technicians. Musk pushes Starlink to replace Verizon. Newark's radar and radios keep going dark because of old copper wire and untested telecom links. Congress puts $12.5B toward the fix and calls it a down payment. June 2026: Air Space Intelligence wins a 12-year FAA contract worth up to $875.9M to build SMART, an AI air traffic management system. Months earlier, ASI's PAC donated to the campaign of Duffy's son-in-law. The award was competitive. ASI's Air Force deal was sole-source. November 10: SMART goes live at all 22 Air Route Traffic Control Centers, about 50 days after its first launch over Washington. The controllers' union says it wasn't involved in the rollout. November 13: An update hits the private network that links every center. The network reboots and crashes, the old equipment chokes, and controllers get bad data. The result is the third nationwide ground stop in US history: more than four hours, nearly 8,000 cancellations and 10,000+ delays. Officials blame old equipment. ASI and Duffy say SMART had nothing to do with it. DHS says it can't rule anything out. Nobody has said what the update was or who approved it. And an earlier review had already warned that this network was no longer supported and that one failure could cut off an entire region. Anyone who has shipped software into legacy infrastructure knows the appropriate playbook: ⭐️ Map every dependency. ⭐️ Test against real failure modes. ⭐️ Run old and new in parallel. ⭐️ Roll out in stages. ⭐️ Change one major thing at a time. ⭐️ Keep a rollback you've actually tested. ⭐️ Keep the operators in the room. I suspect a lot of newer engineers raised on vibecoding have never learned this. Prompting gets something new on screen fast, but it won't teach you how a decades-old network reacts to an update at 4pm on a Friday. Speed is not the metric. In aviation, reliability and accountability have to be built in from day one. Bring back the adults in the room.
1
31
I lived through the first couple of these by being a generalist IT. Been there, done that, good luck, we will get through this one too.
今天外网科技圈都在看微软的笑话。有博主发了一条推文吐槽,说微软之前大裁员 6 万人想用 AI 顶上,结果今天 Microsoft 365 邮件服务在美国和欧洲全线崩了,迟迟修不好——因为懂底层架构、能干活的资深老员工全被裁光了,现在根本没人看得懂这堆祖传代码。 先不管 6 万人这个数字有没有水分,评论区里的反应才是最真实的。伦敦那边的用户说除了 Teams 全挂了,还有法国打工人开心表示“从昨晚六点就没收到过邮件,相当于白嫖一天假期”。 更有意思的是底下有人支招,说干脆自己搭个免费的 SMTP/IMAP 邮件服务器算了,省得受大厂的气。结果博主直接泼了盆冷水:现在电子邮件早就被微软、谷歌和 AWS 垄断成“黑帮地盘”了,自己搭服务器技术上没难度,但你发出去的邮件根本进不了 Gmail 收件箱,大概率直接被当垃圾邮件拒收。 说到底,AI 平时写写代码、当个顺手工具还行,真到了核心系统炸锅的时候,救命的还得是那些知道“屎山”哪块不能动的老师傅。为了财报好看把修水管的人全开了,早晚得淹水。
6
♑️ Kurios Kat retweeted
Replying to @quant_turk
太形象了,这就是典型的“表外负债”。短期财报上的利润率是好看了,但省掉的人力全变成了系统里的隐性技术债,平时看不出来,一旦暴雷就是连本带利一起还。😂
7
74
6,170
Braelyn’s doing the hard part. We’ve secured her treatment—now we need help to carry her through it. Please share 🤍 @PANFoundation @GoodDays_Health @EndBrainCancer @MusellaFdn #Glioblastoma #BrainTumor #CancerSupport $NWBO
1
7
283
♑️ Kurios Kat retweeted
#Glioblastoma $NWBO #DCVax #Immunotherapy #SITC2026 #SITC26 Mel lived the first one. In 1998 a Phase 1 trial took a terminal leukemia and turned it into a disease people grow old with. #Gleevec works because CML runs on one broken switch, BCR-ABL, and one pill can jam it. The common solid tumors never offered one switch. Each carries its own private set of mutations, and when a drug does find a target the tumor rewires around it. That is why there has never been a Gleevec for the cancers that kill most people. DCVax-L does not chase mutations. The patient's own dendritic cells are loaded with the whole tumor, not a chosen piece of it, and the immune system picks the targets. In newly diagnosed glioblastoma that produced 13% alive at five years (or more) against 5.7% for propensity score matched external controls. A curve with a tail is what immune memory looks like. It happened in the textbook cold tumor. Few T cells ever reach a glioblastoma, which is why checkpoint drugs failed there in three Phase 3 trials. A checkpoint drug releases the brakes on T cells that already exist. In a cold tumor there is nothing to release. Dendritic cells sit one step upstream. They create those T cells, so the vaccine does not need the tumor to be warm. It is how a tumor gets warm. And once it is warm, the checkpoint drug that failed alone finally has something to work with. Dr. Liau's UCLA group tested the order in recurrent glioblastoma and reported the result at EANO 2026. In 35 patients, Keytruda before the vaccine meant a median survival of 271 days. Keytruda after the vaccine meant 555 days, and the risk of death fell by two thirds. Tumor and blood showed why: more T cells in the tumor and more interferon and granzyme when the vaccine came first. Same two drugs, same disease. The order alone doubled survival. The trial proved the platform in glioblastoma. The platform never cared which tumor the lysate came from, and the sequence does not care either. 𝗧𝗵𝗮𝘁 𝗶𝘀 𝘁𝗵𝗲 𝘁𝗿𝘂𝗲 𝗚𝗹𝗲𝗲𝘃𝗲𝗰 𝗺𝗼𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝘁𝗵𝗶𝘀 𝘁𝗶𝗺𝗲 𝗶𝘁 𝗶𝘀 𝗳𝗼𝗿 𝗲𝘃𝗲𝗿𝘆 𝘀𝗼𝗹𝗶𝗱 𝘁𝘂𝗺𝗼𝗿. #DCVaxForBraelyn @HollensbeAmanda @ThomasOwenMcCa1 @mfhugo1 @MHRAgovuk @FDA @DrOzCMS @greta @kshaughnessy2 @peterjkostis @Siobhain_Mc @parkerici
Glioblastoma rarely gives good news. The peer-reviewed phase 3 DCVax-L trial showed a statistically significant overall survival benefit in both newly diagnosed and recurrent disease. Brain Tumour Research called the results astonishing. Any validated survival gain matters for patients and families facing this cancer.
1
26
2
91
24,723
True honor True dedication True respect 🇺🇸
What an interesting read........... On Jeopardy the other night, the final question asked: “How many steps does the guard take during his walk across the Tomb of the Unknown?” All three contestants missed it. Tomb of the Unknown Soldier 1. How many steps does the guard take during his walk across the Tomb and why? He takes 21 steps — symbolizing the 21-gun salute, the highest military and foreign tribute. 2. How long does he pause before turning to walk back and why? He waits 21 seconds, again in honor of the same tradition. 3. Why are his gloves damp? They are lightly moistened to ensure he never loses his grip on his rifle. 4. Does he keep his rifle on the same shoulder, and if not, why? He always carries it on the shoulder farthest from the Tomb. After each crossing, he performs an about-face and moves it to the outside shoulder. 5. How often are the guards changed? Every 30 minutes, 24/7, 365 days a year. 6. What are the physical requirements for a Tomb Guard? Applicants must be between 5'10" and 6'2" and have a waist no larger than 30". Other expectations of the Guard: They devote two years to the Tomb, live in the barracks beneath it, and must refrain from drinking alcohol on or off duty for the rest of their lives. They can never swear in public or dishonor the uniform or the Tomb. After two years, they earn a wreath pin signifying their service — fewer than 400 are currently worn. If they violate the code, they must relinquish the pin. Their shoes have thick soles to protect against extreme temperatures and metal heel plates that create the crisp click when they halt. Uniforms must have zero wrinkles or lint and are inspected in a full-length mirror. For the first six months, guards do not speak to anyone and do not watch television. Their off-duty time is spent studying the 175 notable individuals buried at Arlington National Cemetery, memorizing who they are and where they rest. Among them: President Taft, Joe E. Lewis, and Audie Murphy, the most decorated WWII soldier. Every guard spends five hours daily preparing their uniform. ETERNAL REST GRANT THEM, O LORD, AND LET PERPETUAL LIGHT SHINE UPON THEM. When Hurricane Isabel approached Washington, D.C. in 2003, Congress shut down for two days. The guards were offered permission to suspend duty due to danger. They replied: “No way, Sir!” Drenched and marching through the storm, they insisted that guarding the Tomb is the highest honor, not just a task. The Tomb has been continuously guarded — day and night — since 1930. God Bless and Keep Them I don’t often encourage sharing posts, but I would be honored if this one reached as many people as possible. We should always feel proud of the men and women who serve, wherever they are stationed. Duty – Honor – Country IN GOD WE TRUST — with Herbert F Wieland.
Readers added context they thought people might want to know
Some claims in this post are inaccurate. The Society of the Honor Guard says the Tomb has been guarded since 1937, the guard changes hourly in winter, sentinels can drink off duty, and there is no lifetime ban on alcohol or swearing. tombguard.org/society/faq leadstories.com/hoax-alert/202…
5
🚨 TODAY, I submitted my public comment to the FDA regarding its proposed Rare Disease Framework. As the mother of a 19-year-old fighting an aggressive, deadly brain cancer, I have one urgent message: Patients don’t just need faster drug approvals. They need ACCESS to promising treatments while they’re still alive to benefit from them. My comment shares Braelyn’s extraordinary journey, the clinical evidence and long-term survivors associated with DCVax-L, and the enormous barriers American families face trying to access investigational treatments. I also outline Braelyn’s Bill, built around four fundamental patient rights: ❤️ The Right to Know ❤️ The Right to Preserve ❤️ The Right to Choose ❤️ The Right to Access My most urgent request is Braelyn’s Rule: Patients facing life-threatening diseases should be able to access investigational treatments through their physicians, with informed consent and manufacturer participation, without unnecessary regulatory obstacles. We should not have to fly across an ocean to access a promising cancer treatment developed right here in America. The FDA’s new framework must measure success not just by how quickly treatments are evaluated, but by whether patients can actually access them while there’s still time. I’m sharing my full four-page public comment because this fight is about far more than my daughter. It’s about every family who deserves the opportunity to fight for their loved one’s life. Please read and share. ❤️🙏 #BraelynsBill #DCVaxForBraelyn #RareDiseases
3
18
338
Getting close! Please, Help if you are able 🙏💕 #NWBO #BrainCancer #DCVax #DCVaxforBraelyn #FreezeyourTumor #RighttoTryUSA #cancersucks #GBM #glioblastoma #Donations 💖🦋🕊️
❤️ SUNDAY MORNING UPDATE — WE’RE GETTING SO CLOSE! ❤️ In just 12 days, Braelyn will receive her next DCVax-L treatment in London! Since my last fundraising update, more generous people have stepped forward to help us continue her treatment. We are overwhelmed by your kindness and generosity! I’ve carefully reconciled our treatment fund, GoFundMe, GiveSendGo, and private donations to share where we stand. 🎯 Estimated November 6 treatment cost: $30,844 ❤️ TOTAL FUNDS ACCOUNTED FOR: $26,308.02 🎯 ESTIMATED AMOUNT STILL NEEDED: $4,535.98 That’s more than 85% of November’s treatment covered! These figures include donations already deposited, contributions still processing through our fundraising platforms, and private gifts received but not yet deposited. Because treatment is billed in British pounds, the final dollar amount may vary slightly depending on exchange rates and fees. When I look at Braelyn today—cancer-free, attending college, and looking forward to her future—I am reminded why we continue fighting so hard for access to DCVax-L. Thank you to everyone who has donated, shared her story, prayed for her, or encouraged our family. Your generosity has helped make this journey possible. We’re getting so close to covering her November treatment! If you’re able to help us close the remaining gap, we would be incredibly grateful. Every donation, regardless of size, and every share makes a difference. Thank you for helping give Braelyn hope and a future. ❤️🙏 #DCVaxForBraelyn #DCVax #BrainCancer
6
25
527
Prayers, Donated, Shared, Help if you are able! #NWBO #BrainCancer #DCVax #DCVaxforBraelyn #FreezeyourTumor #RighttoTryUSA #cancersucks #GBM #glioblastoma #Donations 💖🦋🕊️
❤️ BRAELYN’S NOVEMBER TREATMENT FUNDRAISER — FULL FINANCIAL UPDATE ❤️ First, THANK YOU to every single person who has donated, shared our story, prayed for Braelyn, or helped us in any way. Your kindness and generosity mean more than words can express. As many of you know, Braelyn was diagnosed with an aggressive, grade 4 brain tumor at just 16 years old. Today, at 19, she is in college and her most recent MRIs show NO EVIDENCE OF CANCER! 🙏❤️ She is receiving DCVax-L, a personalized cancer vaccine developed here in America, but we must travel to London for her treatments because it is not yet available to her in the United States. Her next treatment is November 6, and the cost is approximately $30,600. I want to provide a complete breakdown of our November funding because honesty, transparency, and accountability to everyone who supports Braelyn are extremely important to me. 📊 FINANCIAL UPDATE — OCTOBER 22, 2026 NOVEMBER TREATMENT COST: $30,600 Here is where every dollar currently accounted for stands: 🏦 $20,806.87 — Balance in our dedicated cancer treatment bank account. This includes donations previously transferred from GoFundMe and GiveSendGo, as well as private donations already deposited. ❤️ $865.00 — GiveSendGo donations still held by the platform and not yet transferred to our account. ❤️ $688.34 — GoFundMe donations still processing and not yet transferred. ❤️ $500.00 — Private donation received by check but not yet deposited. TOTAL FUNDS ACCOUNTED FOR: $22,860.21 🎯 STILL NEEDED FOR NOVEMBER 6: $7,739.79 I also want to clarify something about the totals displayed on our fundraising platforms. Both GoFundMe and GiveSendGo show cumulative donations, including money raised for earlier treatments. Those totals are NOT the same as the amount currently available for November. Some of those funds have already been used for previous cancer treatments, and other donations have been transferred into our dedicated treatment account. We count each donation only ONCE, regardless of whether it is still processing, sitting on a fundraising platform, or already deposited in the bank. Our fundraising figures sometimes change quickly as new donations arrive and transfers are processed. I will continue updating everyone as accurately as possible. We are now approximately 75% of the way toward funding Braelyn’s November treatment! ❤️ Just $7,739.79 to go! ❤️ Every donation, regardless of size, brings us closer to getting Braelyn to London for her next DCVax treatment. Our family has been fighting for Braelyn’s hope and future for more than three years. We are incredibly grateful to everyone who continues standing beside her. Please consider donating or sharing this post. Even a repost can help us reach someone who might be able to help. 🙏 Thank you for loving our girl and helping us keep her treatment going! 🔗 DONATE HERE: gofundme.com/f/help-braelyn-… #DCVaxForBraelyn #BrainCancerAwareness
1
3
16
493
❤️ IT’S OFFICIAL! WE’RE MEETING PRESIDENT TRUMP TOMORROW! 🇺🇸 Braelyn and I have been invited to attend tomorrow’s rally for Darline Graham in Clemson! We’ll be seated in the VIP section AND have the opportunity to meet President Trump in the “click line”! Ben is cutting his work trip short, and we’re hoping he’ll make it home in time to join us! We’ll have only seconds with the President, but I intend to make every one of them count. I’ll also be bringing information for him and his staff about Braelyn, DCVax-L, and the barriers American patients face trying to access promising treatments developed right here in the United States. This is an extraordinary opportunity, but we’re hoping it can become something even bigger. PLEASE HELP US GET THE ATTENTION OF THE WHITE HOUSE PRESS TEAM! 🙏 We would love the opportunity for a longer conversation with President Trump or his administration about how we can make these treatments accessible to American patients. Please SHARE, REPOST, and TAG anyone who might help get Braelyn’s story in front of the right people! Three years ago, Braelyn was given just months to live. Today she’s 19, attending college, and her latest MRI shows NO EVIDENCE OF DISEASE RECURRENCE! Her story deserves to be heard. And so do the stories of countless other patients fighting for access to promising treatments. @realDonaldTrump @DrOzCMS @WhiteHouse #DCVaxForBraelyn #DCVax #PresidentTrump
4
36
438
If you need assistance reach out. If you are able to help - this is a valuable cause! 🦋🕊️💖
📣 Our Copayment Assistance Program is OPEN again to new and renewal patients! The Musella Foundation helps eligible brain tumor patients with copayments for covered treatments. If you need financial assistance, please visit our website for eligibility requirements and instructions for new and renewal applications. Learn more and apply: braintumorcopays.org Funding is limited, so please apply promptly. Please share this with patients, caregivers, social workers, and treatment teams. You could help a family find the assistance they need! #BrainTumor #BrainCancer #PatientSupport #MusellaFoundation
1
1
20
$NWBO A video letter to President @realDonaldTrump @HollensbeBrae is the young woman whose Glioblastoma story you recently shared with @DrOzCMS. Braelyn and her parents live ten minutes from Wednesday’s campaign stop in Clemson and would like to meet you. “Today she’s 19 years old, attending college, living her life - and her latest MRI shows no evidence of disease.” Braelyn receives DCVax-L, a promising personalized cancer vaccine developed by American scientists (@NorthwestBio). But she can’t get it in the U.S. Her family has to travel back and forth to England for compassionate use. “For three years I fought to save my daughter‘s life and along the way I’ve discovered just how difficult it is for American patients to access promising investigational treatments - even when those treatments were developed right here in their own country. We need to ask some very serious questions about the barriers facing smaller biotechnology companies, the influence of the pharmaceutical industry, and why patients are left waiting while promising treatments navigate years of regulatory hurdles… …You signed right-to-try into law and I tremendously appreciate what that legislation was intended to accomplish, but I’ve learned firsthand that having the right to request a treatment doesn’t necessarily mean a patient can actually obtain it… An American family shouldn’t have to cross an ocean to receive a promising cancer treatment developed by American scientists…” — @HollensbeAmanda
5
23
306
Spirited little WARRIOR-in-training. She can do this with the support of all you wonderful people. Keep her in your hearts. Keep her in your prayers. And if you can, please contribute whatever you can. No donation is too small. $NWBO gofundme.com/f/help-braelyn-…
6
195
This is wonderfully hopeful and helpful 💝🙏🦋🕊️ #NWBO #DCVax #DCVaxforBraelyn #FreezeYourTumor #Cancer #GBM #CancerAccess
$NWBO | 𝗡𝗛𝗦𝗕𝗧 𝗙𝗢𝗟𝗟𝗢𝗪-𝗨𝗣: 𝗔 𝗖𝗟𝗘𝗔𝗥𝗘𝗥 𝗥𝗢𝗨𝗧𝗘 𝗙𝗥𝗢𝗠 𝗥𝗘𝗙𝗘𝗥𝗥𝗔𝗟 𝗧𝗢 𝗖𝗢𝗟𝗟𝗘𝗖𝗧𝗜𝗢𝗡 A patient’s responsible consultant can refer to Advent Bioservices. Advent coordinates with NHS Blood and Transplant, whose clinician assesses whether the patient is fit for leukapheresis. That is the practical clarification in the October 14 reply from Jemima Churchhouse, NHSBT’s Service Development Manager for Therapeutic Apheresis Services. Following Simon Cliffe’s explanation of “all solid tumours,” I asked how families—particularly those outside the UK—enter the pathway. Jemima has now clarified several responsibilities and connected the discussion with Advent’s clinical liaison team. 𝗪𝗛𝗘𝗥𝗘 𝗧𝗛𝗘 𝗥𝗘𝗙𝗘𝗥𝗥𝗔𝗟 𝗕𝗘𝗚𝗜𝗡𝗦 Jemima states: “The patient does not need to have a UK treating clinician” The patient does need a referring consultant responsible for their overall care and treatment. For overseas families, this identifies a starting point with their existing responsible consultant and Advent, while preserving continuity of care. NHSBT supplies the medical assessment for the collection procedure. Simon’s earlier answer concerned a UK medic’s application for Specials manufacturing. I am seeking a written explanation connecting that requirement with the referral route Jemima described, including who takes responsibility for the manufacturing request. 𝗔𝗗𝗩𝗘𝗡𝗧 𝗜𝗦 𝗡𝗢𝗪 𝗣𝗔𝗥𝗧 𝗢𝗙 𝗧𝗛𝗘 𝗖𝗢𝗥𝗥𝗘𝗦𝗣𝗢𝗡𝗗𝗘𝗡𝗖𝗘 Jemima introduced Lisa Eade, Clinical Liaison Lead at Advent Bioservices, and directed the remaining questions to Advent. She also asked for a 30-minute call to be arranged, with Lisa invited to join. We now have a named Advent contact alongside NHSBT’s collection team. That creates an opportunity to work through the patient journey with both organisations involved. 𝗧𝗛𝗘 𝗣𝗘𝗢𝗣𝗟𝗘 𝗔𝗡𝗗 𝗦𝗬𝗦𝗧𝗘𝗠𝗦 𝗕𝗘𝗛𝗜𝗡𝗗 𝗧𝗛𝗘 𝗥𝗘𝗙𝗘𝗥𝗥𝗔𝗟 NHSBT previously confirmed that DCVax-L collections are underway at Leeds and Oxford. Its published service descriptions show what already exists at those locations: • Leeds, St James’s University Hospital: peripheral blood stem-cell collection, white-cell depletion, plasma exchange and other specialist apheresis procedures. • Oxford, John Radcliffe Hospital: similar collection services, plus extracorporeal photopheresis. NHSBT also lists an Oxford laboratory providing stem-cell and immunotherapy support, and advanced-therapy storage and distribution. Across its licensed and accredited cell-therapy laboratory network, NHSBT describes trained staff handling fresh and frozen cells, controlled freezing, continuously monitored storage, established transport procedures and dedicated quality-assurance teams. For a personalised cell therapy, these capabilities help preserve the patient’s material as it moves between collection, laboratory processing, manufacture and clinical care. NHSBT already supports a comparable organisational model in CAR-T: collection, cryopreservation and storage within its services, with manufacture performed by a third party. 𝗗𝗖𝗩𝗮𝘅-𝗟 𝗶𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗮𝗻 𝗲𝘀𝘁𝗮𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 𝗼𝗳 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻𝘀, 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁𝘀 𝗮𝗻𝗱 𝗰𝗲𝗹𝗹-𝗵𝗮𝗻𝗱𝗹𝗶𝗻𝗴 𝘀𝘆𝘀𝘁𝗲𝗺𝘀. 𝗧𝗛𝗘 𝗣𝗥𝗢𝗖𝗘𝗦𝗦𝗜𝗡𝗚 𝗤𝗨𝗘𝗦𝗧𝗜𝗢𝗡𝗦 𝗛𝗔𝗩𝗘 𝗡𝗢𝗪 𝗕𝗘𝗘𝗡 𝗦𝗘𝗡𝗧 The October 8 announcement includes “specialist cell processing and handling of cellular material” alongside leukapheresis. With the collection route clearer, I have sent NHSBT and Advent a further email asking: • Does the Cellular and Molecular Therapies team’s role cover tumour tissue or tumour cells—including preparation of tumour lysate—immune cells collected through leukapheresis, or both? • Which organisation performs each stage, from receipt and preparation of material through dendritic-cell manufacture? • Which activities are operating now, and which are planned for expansion? The aim is to identify responsibilities across the complete manufacturing pathway. These answers are pending. 𝗧𝗛𝗘 𝗡𝗘𝗫𝗧 𝗔𝗡𝗦𝗪𝗘𝗥𝗦 𝗙𝗔𝗠𝗜𝗟𝗜𝗘𝗦 𝗡𝗘𝗘𝗗 The remaining patient-access questions are already in the correspondence: • What medical records, pathology, tumour tissue and consent materials are required? • Can clinical eligibility and tissue suitability be assessed remotely before travel? • What are the separate timelines for clinical review, manufacturing, product release and treatment? • What are the total self-pay costs, payment arrangements, and expected number and duration of UK visits? • Can these requirements be provided in a written physician-and-patient checklist? NHSBT’s earlier reply described current UK treatment as self-funded. Its usual two-week collection timeframe covers one stage; families need the timing and costs of the complete pathway. We now know where the referral begins, who assesses fitness for collection, and which Advent contact has been introduced. The next step is to connect those responsibilities with the tissue requirements, manufacturing arrangements, appointments and costs a family needs before committing to travel. Thank you to Jemima and Simon for their continued help. I will share substantive answers as they arrive, while respecting the privacy of the correspondence. I am a physician and independent patient advocate, with no affiliation to NWBO or Advent. Sources: NHSBT correspondence, October 12–14, 2026; the official collaboration announcement; NHSBT’s unit, laboratory, stem-cell-service and storage/distribution descriptions. $NWBO #DCVax #GBM #CancerImmunotherapy #PatientAccess #DCVaxForBraelyn
5
234
♑️ Kurios Kat retweeted
$NWBO #DCVaxForBraelyn Joel was just 18 when a brain tumour changed everything. Despite brave treatments, his family and friends are now raising funds for a personalized vaccine that could help prolong his life. This campaign has already reached about 32% of its goal, and every contribution makes a difference. Even if you can't donate, sharing this can help it reach someone who might be able to support. Please consider helping Joel live longer by sharing or donating if you can. gofund.me/53827e4a4
1
17
2
62
1,965